The effect of rosiglitazone on the liver: Decreased gluconeogenesis in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 806-812

  Gastaldelli, Amalia ^a,b,c   Miyazaki, Yoshinori ^c   Pettiti, Maura ^a,b   Santini, Eleonora ^a,b   Ciociaro, Demetrio ^a,b   DeFronzo, Ralph A ^c   Ferrannini, Ele ^c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; BODY FAT; CHRONIC DRUG ADMINISTRATION; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE CLEARANCE; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HUMAN; INSULIN SENSITIVITY; LIVER METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCONEOGENESIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES;

EID: 33644824915     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1159     Document Type: Article

References (47)

1. Spiegelman BM 1998 PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
2. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J 2000 Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells. Diabetologia 43:1165-1169
3. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE 1996 Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 97:2553-2561
4. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS 1997 Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422
5. Takamura T, Nohara E, Nagai Y, Kobayashi K 2001 Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARγ mRNA expression in 3T3-L1 adipocytes. Eur J Pharmacol 422:23-29
6. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791
7. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA 2004 Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206
8. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK 2000 A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275:5754-5759
9. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA 2001 Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719
10. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA 2001 Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219
11. Raman P, Foster SE, Stokes MC, Strenge JK, Judd RL 1998 Effect of troglitazone (Rezulin) on fructose 2,6-bisphosphate concentration and glucose metabolism in isolated rat hepatocytes. Life Sci 62:PL89-PL94
12. Raman P, Judd RL 2000 Role of glucose and insulin in thiazolidinedioneinduced alterations in hepatic gluconeogenesis. Eur J Pharmacol 409:19-29
13. Adams MD, Raman P, Judd RL 1998 Comparative effects of englitazone and glyburide on gluconeogenesis and glycolysis in the isolated perfused rat liver. Biochem Pharmacol 55:1915-1920
14. Nishimura Y, Inoue Y, Takeuchi H, Oka Y 1997 Acute effects of pioglitazone on glucose metabolism in perfused rat liver. Acta Diabetol 34:206-210
15. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA 2001 Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277
16. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA 1998 Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther 284:751-759
17. Saltiel AR, Olefsky JM 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:751-759
18. Schumann WC, Gastaldelli A, Chandramouli V, Previs SF, Pettiti M, Ferrannini E, Landau BR 2001 Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H2O administration. Anal Biochem 297:195-197
19. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC 1996 Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98:378-385
20. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E 2000 Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373
21. Previs S, Hazey J, Diraison F, Beylot M, David F, Brunengraber H 1996 Assay of the deuterium enrichment of water via acetylene. J Mass Spectr 31:389-391
22. Bonora E, Del Prato S, Bonadonna R, Gulli G, Solini A, Shank M, Ghiatas A, Lancaster J, Kilcoyne R, Alyassin A, DeFronzo R 1992 Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 41:1151-1159
23. Lancaster J, Ghiatas A, Alyassin A, Kilcoyne R, Bonora E, DeFronzo RA 1991 Measurement of abdominal fat with T1-weighted MR images. J Magnetic Resonance Imaging 1:363-369
24. Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E 2000 Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 43:1266-1272
25. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD 1998 Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 47:523-529
26. DeFronzo RA, Ferrannini E, Simonson DC 1989 Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395
27. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA 1989 Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. J Clin Invest 84:205-213
28. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quinones-Galvan A, Sironi AM, Natali A, Ferrannini E 2001 Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50:1807-1812
29. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti Jr JR 2001 Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism 50:963-971
30. Gastaldelli A, Miyazaki Y, Pettiti M, Buzzigoli E, Mahankali S, Ferrannini E, DeFronzo RA 2004 Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 89:3914-3921
31. Edgerton D, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumann W, Landau B, Rossetti L, Cherrington A 2001 Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50:1872-1882
32. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M 2004 Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629
33. Bays H, Mandarino L, DeFronzo RA 2004 Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478
34. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E 2004 Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27:1349-1357
35. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162
36. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA 2003 Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370
37. Fonseca V 2003 Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115:42S-48S
38. Asnani S, Richard BC, Desouza C, Fonseca V 2003 Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin 19:609-613
39. Makimattila S, Nikkila K, Yki-Jarvinen H 1999 Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 42:406-412
40. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P, Nuutila P 2003 Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290
41. Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P 2003 Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 26:2069-2074
42. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E 2002 Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 87:5098-5103
43. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhausl W, Shulman GI 2000 Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707
44. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD 2004 Splanchnic lipolysis in human obesity. J Clin Invest 113:1582-1588
45. Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, Ellmerer M 2001 Central role of the adipocyte in the metabolic syndrome. J Invest Med 49:119-126
46. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H 2004 Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176
47. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA 2004 Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783-789